Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $75.2 million.

  • Innate Pharma's Cash & Equivalents fell 115.22% to $75.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $75.2 million, marking a year-over-year decrease of 115.22%. This contributed to the annual value of $71.0 million for FY2024, which is 660.33% down from last year.
  • As of Q2 2025, Innate Pharma's Cash & Equivalents stood at $75.2 million, which was down 115.22% from $71.0 million recorded in Q4 2024.
  • Over the past 5 years, Innate Pharma's Cash & Equivalents peaked at $164.7 million during Q2 2021, and registered a low of $71.0 million during Q4 2024.
  • Its 5-year average for Cash & Equivalents is $96.7 million, with a median of $85.9 million in 2022.
  • In the last 5 years, Innate Pharma's Cash & Equivalents tumbled by 9987.48% in 2021 and then tumbled by 115.22% in 2025.
  • Quarter analysis of 5 years shows Innate Pharma's Cash & Equivalents stood at $118.7 million in 2021, then dropped by 27.6% to $85.9 million in 2022, then decreased by 11.59% to $76.0 million in 2023, then fell by 6.6% to $71.0 million in 2024, then rose by 5.93% to $75.2 million in 2025.
  • Its Cash & Equivalents stands at $75.2 million for Q2 2025, versus $71.0 million for Q4 2024 and $76.0 million for Q2 2024.